This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
Metalyse is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left\-bundle\-branch block within six hours after the onset of acute\-myocardial\-infarction symptoms. Metalyse is indicated in adults for the thrombolytic treatment of acute ischaemic stroke (AIS) within 4\.5 hours from last known well and after exclusion of intracranial haemorrhage.
Therapeutic Area (MeSH)
ATC Code
B01AD11
ATC Item
N/A
Pharmacotherapeutic Group
Antithrombotic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| tenecteplase | N/A | tenecteplase |
EMA Name
Metalyse
Medicine Name
Metalyse
Aliases
N/ANo risk management plan link.
